Cite
HARVARD Citation
Avet-Loiseau, H. et al. (2021). Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. Journal of clinical oncology. 39 (10), pp. 1139-1149. [Online].